 |
 |
Brian wrote in part: <<<Ron responded to my first issue of this note with a lengthy account which I suspect came straight out of the drug makers press release. It makes my point nicely which is that until proven by clinical tests, the sort of high-sounding claims quoted by Ron are best regarded as waffle or flute music (as we call it).>>> Some of the words were from the 52-page supplement 10, An algorithm for the Management of Parkinson's Disease, December 1994 volume 44 of Neurology, Official Journal of the American Academy of Neurology, pages S16 and S17 section on dopamine agonists. references 46 through 55 of the supplement edited by Doctors Koller, Silver and Lieberman pertain to agonist usage. I do not have copies of any of those. NPF Parkinson Report vol XVIII issue II was mostly devoted to "Up and Coming Medical Therapies for Parkinson's Disease" with this being the title of the lead cover article by Matthias Kurth,MD,PhD; and the second article by Profesor Peter Jenner, London. I recommend perusal of both these references - plus; keep a cynical peristence to have the data verified - and know that knowledge regarding any science or practice is subject to revision by learning more. Do not let yourself ingest more than the minimum number of these interactive chemicals. levodopa is the natural chemical precursor to dopamine; and none of the agonists do exactly the same processes. morphine and apomorphine have their uses and their problems. dopamine-receptor sites are involved with our movement and most of the emotional networks as well. take care. best wishes to all of us. -- Ron Vetter 1936, '84 PD dz 'paradise is where you make it, not a place to go' janet [log in to unmask] http://www.ridgecrest.ca.us/~rfvetter